{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:22:15Z","timestamp":1789514535999,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangzhou Science and Technology, Basic and Applied Basic Research Topic","award":["2024A04J4987"],"award-info":[{"award-number":["2024A04J4987"]}]},{"name":"Foundation of Guangzhou Women and Children\u2019s Medical Center","award":["2023BS036"],"award-info":[{"award-number":["2023BS036"]}]},{"name":"Foundation of Guangzhou Women and Children\u2019s Medical Center","award":["2021BS023"],"award-info":[{"award-number":["2021BS023"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203112"],"award-info":[{"award-number":["82203112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102791"],"award-info":[{"award-number":["82102791"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201522"],"award-info":[{"award-number":["82201522"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271650"],"award-info":[{"award-number":["82271650"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172917"],"award-info":[{"award-number":["82172917"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36983-4","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:23:20Z","timestamp":1769880200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the prognostic significance of HIST1H4C in breast cancer: implications for neoadjuvant therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Li","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Haihu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Cairong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Yuanxuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao","family":"Yongdong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Xiaofeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"jingjing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"3","key":"36983_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"36983_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Primers. 5 (1), 66 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"36983_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/GCO.0000000000000147","volume":"27","author":"S Loibl","year":"2015","unstructured":"Loibl, S. Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis. Curr. Opin. Obstet. Gynecol. 27 (1), 85\u201391 (2015).","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"5","key":"36983_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi, P. et al. Preoperative chemotherapy: updates of National surgical adjuvant breast and bowel project protocols B-18 and B-27. J. Clin. Oncol. 26 (5), 778\u2013785 (2008).","journal-title":"J. Clin. Oncol."},{"key":"36983_CR5","doi-asserted-by":"publisher","first-page":"e066381","DOI":"10.1136\/bmj-2021-066381","volume":"375","author":"F Conforti","year":"2021","unstructured":"Conforti, F. et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ 375, e066381 (2021).","journal-title":"BMJ"},{"issue":"9938","key":"36983_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384 (9938), 164\u2013172 (2014).","journal-title":"Lancet"},{"issue":"11","key":"36983_CR7","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1001\/jamaoncol.2021.3690","volume":"7","author":"WF Symmans","year":"2021","unstructured":"Symmans, W. F. et al. Assessment of residual cancer burden and Event-Free survival in neoadjuvant treatment for High-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial. JAMA Oncol. 7 (11), 1654\u20131663 (2021).","journal-title":"JAMA Oncol."},{"issue":"8","key":"36983_CR8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1634\/theoncologist.2016-0423","volume":"22","author":"Y Xu","year":"2017","unstructured":"Xu, Y. et al. Association study confirmed three breast Cancer-Specific molecular Subtype-Associated susceptibility loci in Chinese Han women. Oncologist 22 (8), 890\u2013894 (2017).","journal-title":"Oncologist"},{"issue":"19","key":"36983_CR9","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1200\/JCO.2007.15.5986","volume":"26","author":"EA Rakha","year":"2008","unstructured":"Rakha, E. A. et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J. Clin. Oncol. 26 (19), 3153\u20133158 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"36983_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41523-022-00478-y","volume":"8","author":"R Jaroensri","year":"2022","unstructured":"Jaroensri, R. et al. Deep learning models for histologic grading of breast cancer and association with disease prognosis. NPJ Breast Cancer. 8 (1), 113 (2022).","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"36983_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41598-023-27787-x","volume":"13","author":"NA Hottat","year":"2023","unstructured":"Hottat, N. A. et al. Assessment of diffusion-weighted MRI in predicting response to neoadjuvant chemotherapy in breast cancer patients. Sci. Rep. 13 (1), 614 (2023).","journal-title":"Sci. Rep."},{"issue":"4","key":"36983_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.suronc.2008.03.003","volume":"17","author":"M Tewari","year":"2008","unstructured":"Tewari, M., Krishnamurthy, A. & Shukla, H. S. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg. Oncol. 17 (4), 301\u2013311 (2008).","journal-title":"Surg. Oncol."},{"issue":"4","key":"36983_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","volume":"268","author":"OM Fayanju","year":"2018","unstructured":"Fayanju, O. M. et al. The clinical significance of breast-only and Node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): A review of 20,000 breast cancer patients in the National cancer data base (NCDB). Ann. Surg. 268 (4), 591\u2013601 (2018).","journal-title":"Ann. Surg."},{"issue":"10","key":"36983_CR14","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.ejca.2004.03.014","volume":"40","author":"A Vincent-Salomon","year":"2004","unstructured":"Vincent-Salomon, A. et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur. J. Cancer. 40 (10), 1502\u20131508 (2004).","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"36983_CR15","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74 (1), 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"36983_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/tbj.12568","volume":"22","author":"G Vugts","year":"2016","unstructured":"Vugts, G. et al. Patterns of care in the administration of Neo-adjuvant chemotherapy for breast Cancer. A Population-Based study. Breast J. 22 (3), 316\u2013321 (2016).","journal-title":"Breast J."},{"issue":"15","key":"36983_CR17","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/cncr.29348","volume":"121","author":"SS Mougalian","year":"2015","unstructured":"Mougalian, S. S. et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the united States. Cancer 121 (15), 2544\u20132552 (2015).","journal-title":"Cancer"},{"issue":"8","key":"36983_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrclinonc.2016.1","volume":"13","author":"F Penault-Llorca","year":"2016","unstructured":"Penault-Llorca, F. & Radosevic-Robin, N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat. Rev. Clin. Oncol. 13 (8), 487\u2013503 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"36983_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21037\/cco.2018.09.05","volume":"7","author":"EN Imyanitov","year":"2018","unstructured":"Imyanitov, E. N. & Yanus, G. A. Neoadjuvant therapy: theoretical, biological and medical consideration. Chin. Clin. Oncol. 7 (6), 55 (2018).","journal-title":"Chin. Clin. Oncol."},{"issue":"7","key":"36983_CR20","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"20","author":"RN Amaria","year":"2019","unstructured":"Amaria, R. N. et al. Neoadjuvant systemic therapy in melanoma: recommendations of the international neoadjuvant melanoma consortium. Lancet Oncol. 20 (7), e378\u2013e389 (2019).","journal-title":"Lancet Oncol."},{"key":"36983_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-016-2652-z","volume":"16","author":"X Jin","year":"2016","unstructured":"Jin, X. et al. A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer. BMC Cancer. 16, 606 (2016).","journal-title":"BMC Cancer"},{"issue":"1","key":"36983_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10549-017-4155-2","volume":"163","author":"B Goorts","year":"2017","unstructured":"Goorts, B. et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 163 (1), 83\u201391 (2017).","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"36983_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque, W. et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res. Treat. 170 (3), 559\u2013567 (2018).","journal-title":"Breast Cancer Res. Treat."},{"issue":"9","key":"36983_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2217\/fon-2016-0420","volume":"13","author":"X Chen","year":"2017","unstructured":"Chen, X. et al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Future Oncol. 13 (9), 843\u2013857 (2017).","journal-title":"Future Oncol."},{"issue":"1","key":"36983_CR25","doi-asserted-by":"publisher","first-page":"7671","DOI":"10.1038\/s41598-018-26114-z","volume":"8","author":"T Ishiguro","year":"2018","unstructured":"Ishiguro, T. et al. Malonylation of histone H2A at lysine 119 inhibits Bub1-dependent H2A phosphorylation and chromosomal localization of Shugoshin proteins. Sci. Rep. 8 (1), 7671 (2018).","journal-title":"Sci. Rep."},{"key":"36983_CR26","doi-asserted-by":"publisher","first-page":"8168517","DOI":"10.1155\/2022\/8168517","volume":"2022","author":"X Ye","year":"2022","unstructured":"Ye, X. et al. E2F1 affects the therapeutic response to neoadjuvant therapy in breast cancer. Dis. Markers. 2022, 8168517 (2022).","journal-title":"Dis. Markers"},{"issue":"4","key":"36983_CR27","doi-asserted-by":"publisher","first-page":"114066","DOI":"10.1016\/j.celrep.2024.114066","volume":"43","author":"EL Roberts","year":"2024","unstructured":"Roberts, E. L. et al. CDK activity at the centrosome regulates the cell cycle. Cell. Rep. 43 (4), 114066 (2024).","journal-title":"Cell. Rep."},{"issue":"7","key":"36983_CR28","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1073\/pnas.0914874107","volume":"107","author":"G Pascreau","year":"2010","unstructured":"Pascreau, G., Eckerdt, F., Churchill, M. E. & Maller, J. L. Discovery of a distinct domain in Cyclin A sufficient for centrosomal localization independently of Cdk binding. Proc. Natl. Acad. Sci. U S A. 107 (7), 2932\u20132937 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"2","key":"36983_CR29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bcp.2010.03.029","volume":"80","author":"ZZ Wu","year":"2010","unstructured":"Wu, Z. Z., Lu, H. P. & Chao, C. C. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem. Pharmacol. 80 (2), 262\u2013276 (2010).","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"36983_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13058-016-0676-6","volume":"18","author":"M Braunstein","year":"2016","unstructured":"Braunstein, M. et al. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer. Breast Cancer Res. 18 (1), 16 (2016).","journal-title":"Breast Cancer Res."},{"issue":"4","key":"36983_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10637-010-9395-5","volume":"29","author":"U Olszewski","year":"2011","unstructured":"Olszewski, U. et al. Anticancer activity and mode of action of titanocene C. Invest. New. Drugs. 29 (4), 607\u2013614 (2011).","journal-title":"Invest. New. Drugs"},{"issue":"11","key":"36983_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2217\/fon.16.22","volume":"12","author":"F Fidalgo","year":"2016","unstructured":"Fidalgo, F. et al. Role of rare germline copy number variation in melanoma-prone patients. Future Oncol. 12 (11), 1345\u20131357 (2016).","journal-title":"Future Oncol."},{"issue":"1","key":"36983_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41598-017-00219-3","volume":"7","author":"K Ohshima","year":"2017","unstructured":"Ohshima, K. et al. Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors. Sci. Rep. 7 (1), 641 (2017).","journal-title":"Sci. Rep."},{"issue":"1","key":"36983_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.canlet.2011.03.013","volume":"307","author":"V Mirisola","year":"2011","unstructured":"Mirisola, V. et al. A prognostic multigene classifier for squamous cell carcinomas of the larynx. Cancer Lett. 307 (1), 37\u201346 (2011).","journal-title":"Cancer Lett."},{"issue":"6","key":"36983_CR35","first-page":"4893","volume":"18","author":"W Xie","year":"2019","unstructured":"Xie, W. et al. Expression and potential prognostic value of histone family gene signature in breast cancer. Exp. Ther. Med. 18 (6), 4893\u20134903 (2019).","journal-title":"Exp. Ther. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36983-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36983-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36983-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:17:09Z","timestamp":1771413429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36983-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36983"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36983-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6792"}}